Display options
Cite
Martinez Sanz P, van Rees DJ, Matlung HL, et al. Response to: Correspondence on "G-CSF as a suitable alternative to GM-CSF to boost dinutuximab-mediated neutrophil cytotoxicity in neuroblastoma treatment" by Mora . J Immunother Cancer. 2021;9(12)doi: 10.1136/jitc-2021-003983.
Martinez Sanz, P., van Rees, D. J., Matlung, H. L., Tytgat, G. A. M., & Franke, K. (2021). Response to: Correspondence on "G-CSF as a suitable alternative to GM-CSF to boost dinutuximab-mediated neutrophil cytotoxicity in neuroblastoma treatment" by Mora . Journal for immunotherapy of cancer, 9(12), . https://doi.org/10.1136/jitc-2021-003983
Martinez Sanz, Paula, et al. "Response to: Correspondence on "G-CSF as a suitable alternative to GM-CSF to boost dinutuximab-mediated neutrophil cytotoxicity in neuroblastoma treatment" by Mora ." Journal for immunotherapy of cancer vol. 9,12 (2021). doi: https://doi.org/10.1136/jitc-2021-003983
Martinez Sanz P, van Rees DJ, Matlung HL, Tytgat GAM, Franke K. Response to: Correspondence on "G-CSF as a suitable alternative to GM-CSF to boost dinutuximab-mediated neutrophil cytotoxicity in neuroblastoma treatment" by Mora . J Immunother Cancer. 2021 Dec;9(12). doi: 10.1136/jitc-2021-003983. PMID: 34893526.
Copy Download .nbib Format: NLM
Share it on

J Immunother Cancer. 2021 Dec;9(12). doi: 10.1136/jitc-2021-003983.

Response to: Correspondence on "G-CSF as a suitable alternative to GM-CSF to boost dinutuximab-mediated neutrophil cytotoxicity in neuroblastoma treatment" by Mora .

Journal for immunotherapy of cancer

Paula Martinez Sanz, Dieke J van Rees, Hanke L Matlung, Godelieve A M Tytgat, Katka Franke

Affiliations

  1. Department of Blood Cell Research, Sanquin Research, Amsterdam, The Netherlands [email protected].
  2. Department of Blood Cell Research, Sanquin Research, Amsterdam, The Netherlands.
  3. Department of Pediatric Oncology, Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.

PMID: 34893526 DOI: 10.1136/jitc-2021-003983

[No abstract available.]

Keywords: cytokines; immunotherapy; neuroblastoma

Conflict of interest statement

Competing interests: None declared.

Publication Types